2024 audits of ISO 13485 from DEKRA confirm Spark Biomedical meets international standards for quality management systems.

Spark Biomedical launches a unique fellowship program that enables neurosurgery residents to collaborate with medical device industry leaders advancing technology and shaping the future of healthcare.

Spark Biomedical is joined by the Battelle Memorial Institute and Hazelden Betty Ford Foundation to begin pioneering an AI-powered, wearable, closed-loop neurostimulation system to improve opioid withdrawal treatment retention and reduce relapse and overdose rates.

Spark Biomedical unveils the Sparrow® Link Research Platform designed to enable research teams to customize the transcutaneous auricular neurostimulation tAN power of the FDA-cleared Sparrow Ascent.

The Centers for Medicare and Medicaid Services codes will help increase accessibility to wearable bioelectric medicine for opioid withdrawal.

Entrepreneur of the Year celebrates ambitious entrepreneurs who are shaping the future.

Pathway to Cures (P2C) announced today its investment of $500,000 in Five Liters, a subsidiary of Spark Biomedical, to develop therapies for treating inheritable blood and bleeding disorders. Pathway to Cures, an affiliate of the National Bleeding Disorders Foundation, is a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.

The partnership focuses on testing wearable neurostimulation to prevent and treat acute stress reaction in the military. 

Spark Biomedical Inc., a U.S. leader in wearable neurostimulation solutions, is proud to announce the launch of telehealth services for their recently FDA-cleared product, Sparrow Ascent.

This FDA-cleared wearable neuromodulation system offers game-changing access for patients to start the road to recovery without interruptions to daily living